Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for Sept. 14-16, 2026, at the Lotte New York Palace Hotel. This presentation is significant as it provides a platform for the company to detail its innovative approach to addressing one of the most pressing challenges in oncology: drug resistance.
The presentation comes at a critical time for Kairos Pharma, which is developing ENV-105, an antibody targeting CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This mechanism could potentially transform treatment paradigms for patients who have limited options after their cancers become resistant to current drugs.
The conference, organized by H.C. Wainwright & Co., is one of the most anticipated events in the investment community, bringing together leading biotech and pharma companies with institutional investors, analysts, and industry experts. For Kairos Pharma, presenting at this venue not only raises its profile among potential investors but also validates the scientific promise of its pipeline. The company's focus on structural biology to overcome drug resistance and immune suppression sets it apart from many peers, and the presentation will likely delve into the science behind ENV-105 and its potential impact on patient outcomes.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to design molecules that specifically target resistance mechanisms. The lead candidate, ENV-105, has shown promise in preclinical studies, and the company is advancing it through clinical development. The H.C. Wainwright presentation offers an opportunity for the company to communicate its progress and future milestones to a wide audience, which could be pivotal for securing the partnerships and funding needed to accelerate development.
The announcement also highlights the growing interest in innovative approaches to cancer treatment, particularly those that address resistance. Standard therapies often fail over time due to resistance mechanisms, and companies like Kairos Pharma are exploring ways to overcome these barriers. By targeting CD105, ENV-105 could potentially be used in combination with existing treatments to prolong their effectiveness, offering new hope for patients with difficult-to-treat cancers.
Investors and stakeholders will be watching closely as Kairos Pharma presents its corporate overview. The company's commitment to addressing drug resistance is timely, as the oncology community increasingly recognizes the need for strategies that extend the durability of treatment responses. The presentation at the H.C. Wainwright conference is a key step in communicating how ENV-105 might fit into the evolving landscape of cancer therapy.
For more information about Kairos Pharma, including the latest news and updates, visit the company's newsroom at https://ibn.fm/KAPA. The full press release is available at https://ibn.fm/NrBQD.
